12 Month Price Forecast For CUE
Distance to CUE Price Forecasts
CUE Price Momentum
🤔 Considering Cue Biopharma (CUE)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 5:26 AM UTC
CUE Analyst Ratings & Price Targets
Based on our analysis of 8 Wall Street analysts, CUE has a consensus that is bullish. The median price target is $4.00, with forecasts ranging from $2.00 to $6.00. Currently, there are 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With CUE currently trading at $1.21, the median price forecast suggests a 230.6% upside. The most optimistic forecast comes from Maury Raycroft at Jefferies, projecting a 395.9% upside, while Reni Benjamin at JMP Securities provides the most conservative target, suggesting a 65.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CUE Analyst Consensus
CUE Price Target Range
Latest CUE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CUE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 20, 2024 | Stifel | Stephen Willey | Buy | Maintains | $4.00 |
| Jul 26, 2024 | JMP Securities | Reni Benjamin | Market Outperform | Maintains | $2.00 |
| Jul 26, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $3.00 |
| Apr 9, 2024 | Oppenheimer | Leland Gershell | Outperform | Maintains | $10.00 |
| Apr 9, 2024 | Stifel | Stephen Willey | Buy | Maintains | $8.00 |
| Apr 3, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $8.00 |
| Mar 13, 2024 | Jefferies | Maury Raycroft | Buy | Initiates | $6.00 |
| Nov 6, 2023 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $8.00 |
| Jun 26, 2023 | Oppenheimer | Mark Breidenbach | Outperform | Assumes | $10.00 |
| Jun 15, 2023 | Stifel | Stephen Willey | Buy | Reiterates | $8.00 |
| May 15, 2023 | JMP Securities | Reni Benjamin | Outperform | Reiterates | $15.00 |
| Mar 22, 2023 | Stifel | Stephen Willey | Buy | Maintains | $8.00 |
| Mar 22, 2023 | Oppenheimer | Mark Breidenbach | Outperform | Reiterates | $10.00 |
| Nov 21, 2022 | Piper Sandler | Edward Tenthoff | Overweight | Initiates | $7.00 |
| Aug 24, 2022 | Oppenheimer | Mark Breidenbach | Outperform | Maintains | $10.00 |
| Mar 21, 2022 | Oppenheimer | Mark Breidenbach | Outperform | Maintains | $26.00 |
| Mar 18, 2022 | Craig-Hallum | Robin Garner | Buy | Maintains | $26.00 |
| Nov 24, 2020 | Berenberg | Buy | Initiates | $0.00 | |
| May 20, 2020 | Stifel | Buy | Maintains | $30.00 | |
| May 20, 2020 | Oppenheimer | Outperform | Maintains | $32.00 |
Stocks Similar to Cue Biopharma Inc
The following stocks are similar to Cue Biopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cue Biopharma Inc (CUE) Financial Data
Cue Biopharma Inc has a market capitalization of $76.65M with a P/E ratio of -1.1x. The company generates $8.30M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +92.3% quarter-over-quarter, while maintaining an operating margin of -390.6% and return on equity of -138.9%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Cue Biopharma Inc (CUE) Company Overview
About Cue Biopharma Inc
Develops injectable therapeutics for cancer treatment.
The company operates as a clinical-stage biopharmaceutical entity, focusing on developing innovative injectable therapeutics that specifically target and modulate T cells to treat various cancers and diseases. It generates revenue through collaboration agreements, strategic partnerships, and licensing deals with other pharmaceutical companies and research institutions, enabling the advancement of its drug candidates.
Cue Biopharma's lead candidate, CUE-101, targets HPV16+ recurrent/metastatic head and neck cancer. The company is also working on several other drug candidates and programs outside of oncology. With a strong focus on collaboration, it has established partnerships with notable entities like LG Chem, Ono Pharmaceutical, and Albert Einstein College of Medicine, facilitating its research and development efforts.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
53
CEO
Mr. Daniel R. Passeri J.D., M.Sc.
Country
United States
IPO Year
2018
Website
www.cuebiopharma.comCue Biopharma Inc (CUE) Latest News & Analysis
Cue Biopharma granted an inducement option award to new interim CDO Daniel Baker, M.D., approved by independent directors, in line with Nasdaq rules. The firm focuses on T cell-targeted therapies.
The appointment of a new interim chief development officer and the associated stock option grant may signal a strategic shift or renewed focus for Cue Biopharma, impacting future growth potential and investor confidence.
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
1 month agoCue Biopharma, Inc. (Nasdaq: CUE) will participate in a fireside discussion at the Piper Sandler 36th Annual Healthcare Conference in New York from Dec 3-5, 2024.
Cue Biopharma's participation in a major healthcare conference highlights its visibility and potential investor interest, which could impact stock performance and market perception.
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
2 months agoCue Biopharma, Inc. (Nasdaq: CUE) has released its Q3 2024 business and financial update, focusing on its development of biologics for cancer and autoimmune disease treatment.
Cue Biopharma's Q3 update may reveal financial health and progress in drug development, impacting stock valuation and investor sentiment in the biopharmaceutical sector.
Cue Biopharma, Inc. reported a quarterly loss of $0.17 per share, beating the Zacks Consensus Estimate of $0.20 and improving from a loss of $0.24 per share a year earlier.
Cue Biopharma's smaller-than-expected loss indicates improving financial performance, potentially boosting investor confidence and impacting stock valuation positively.
Cue Biopharma appoints Dr. Daniel Baker as interim chief development officer starting November 25, 2024. Dr. Anish Suri will transition to principal research and immunology advisor.
Leadership changes can impact a company's strategic direction and investor confidence. Dr. Baker's appointment could signal a shift in development priorities, affecting stock performance.
Cue Biopharma presented updated Phase 1 trial data for CUE-101, targeting recurrent/metastatic head and neck squamous cell carcinoma, at the SITC 2024 conference in Houston.
Cue Biopharma's updated trial data for CUE-101 could indicate progress in cancer treatment, potentially increasing the company's stock value and investor interest in its future prospects.
Frequently Asked Questions About CUE Stock
What is Cue Biopharma Inc's (CUE) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Cue Biopharma Inc (CUE) has a median price target of $4.00. The highest price target is $6.00 and the lowest is $2.00.
Is CUE stock a good investment in 2025?
According to current analyst ratings, CUE has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.21. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CUE stock?
Wall Street analysts predict CUE stock could reach $4.00 in the next 12 months. This represents a 230.6% increase from the current price of $1.21. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cue Biopharma Inc's business model?
The company operates as a clinical-stage biopharmaceutical entity, focusing on developing innovative injectable therapeutics that specifically target and modulate T cells to treat various cancers and diseases. It generates revenue through collaboration agreements, strategic partnerships, and licensing deals with other pharmaceutical companies and research institutions, enabling the advancement of its drug candidates.
What is the highest forecasted price for CUE Cue Biopharma Inc?
The highest price target for CUE is $6.00 from Maury Raycroft at Jefferies, which represents a 395.9% increase from the current price of $1.21.
What is the lowest forecasted price for CUE Cue Biopharma Inc?
The lowest price target for CUE is $2.00 from Reni Benjamin at JMP Securities, which represents a 65.3% increase from the current price of $1.21.
What is the overall CUE consensus from analysts for Cue Biopharma Inc?
The overall analyst consensus for CUE is bullish. Out of 8 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are CUE stock price projections?
Stock price projections, including those for Cue Biopharma Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
